Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $499 from $467 and keeps an Equal Weight rating on the shares. The company announced slight miss in Q1 and revision up to the lower end of revenue guidance, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Wolfe downgrades Vertex Pharmaceuticals on slow pain launch
- Vertex Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Vertex downgraded to Peer Perform from Outperform at Wolfe Research
- Vertex Pharmaceuticals price target raised to $621 from $617 at Goldman Sachs
- Vertex Pharmaceuticals price target lowered to $442 from $450 at Scotiabank